Company profile

BillionToOne

BillionToOne, founded in 2015 in San Francisco, California, is a unicorn genomics company developing cell-free liquid biopsy tests for cancer and genetic disorders. The company has raised a total of $389M, including a $130M Series D on June 21, 2024, led by Premji Invest, reaching a $1B valuation. With investors such as Baillie Gifford and Premji Invest, BillionToOne leverages its proprietary molecular counter platform to advance precision diagnostics, expand oncology testing, and make molecular testing more accessible globally.

Back to profiles

Quick facts

Total funding: $389M
Valuation: $1B
Founded: 2015

Notable investors

Premji Invest

Reach buyers like BillionToOne on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like BillionToOne
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like BillionToOne.

The 14-day trial ships every feature, no card required.

Start free →